Caplin Point Laboratories Ltd Quarterly Results
Q4 FY25-26 Results Summary
Revenue
The revenue stands at ₹600.16 crore, reflecting a quarter-on-quarter *(QoQ) increase of 10.57 per cent from ₹542.77 crore. This corresponds to a year-on-year *(YoY) growth of 19.45 per cent.
Operating Profit
Operating Profit stands at ₹204.24 crore, reflecting a quarter-on-quarter *(QoQ) increase of 7.68 per cent from ₹189.67 crore. This corresponds to a year-on-year *(YoY) growth of 21.53 per cent.
PBDT
PBDT stands at ₹232.24 crore, reflecting a quarter-on-quarter *(QoQ) increase of 4.06 per cent from ₹223.17 crore. This corresponds to a year-on-year *(YoY) growth of 19.89 per cent.
Profit Before Tax
Profit Before Tax stands at ₹213.44 crore, reflecting a quarter-on-quarter *(QoQ) increase of 4.68 per cent from ₹203.89 crore. This corresponds to a year-on-year *(YoY) growth of 20.81 per cent.
Net Profit
Net Profit stands at ₹172.88 crore, reflecting a quarter-on-quarter *(QoQ) increase of 4.23 per cent from ₹165.86 crore. This represents a 19.00 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Market News
Caplin Point Laboratories Ltd Earnings
- YOY
- QOQ
Caplin Point Laboratories Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Caplin Point Laboratories Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Caplin Point Laboratories Ltd Financial Reports
Caplin Point Laboratories Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Caplin Point Lab | 0.37% | 2.33% | 15.04% | 17.39% | 6.33% | -7.28% |
| Cohance Life | -0.50% | -2.58% | 14.99% | 33.08% | -26.71% | -61.39% |
| Jubilant Pharmo | -1.12% | -1.40% | 5.36% | 10.66% | -7.30% | -7.13% |
| Rubicon Research | -1.63% | -4.70% | 2.51% | 22.41% | 45.01% | 51.57% |
| Alembic Pharma | 1.04% | 4.34% | -1.87% | -2.00% | -16.44% | -22.22% |
| Alivus Life | -2.18% | -1.52% | -1.99% | 14.67% | 15.87% | -6.77% |
| Concord Biotech | 2.66% | 2.49% | 9.60% | 4.81% | -18.35% | -25.03% |
Company Info
Company Information
Chairman & Non Executive Dir. : C C Paarthipan
Non Independent Executive Director / MD : Sridhar Ganesan
Independent Non Exe. Director : R Vijayaraghavan
Independent Non Exe. Director : C K Gariyali
Independent Non Exe. Director : Deenadayalan Singaram
Independent Non Exe. Director : R Nagendran
Co. Sec. / Comp. Officer / General Counsel : VENKATRAM GANAPATHYSUBRAMANIAN
Additional Director : K C John
Vice Chairman & Additional Director : ASHOK GORKEY PARTHEEBAN
Vice Chairman & Additional Director : PARTHEEBAN VIVEK SIDDARTH